Analisi critica di un campione di farmaci oncologici valutati dalla Commissione Tecnica Regionale della Regione Veneto

In recent years, anticancer drug treatment was the main driver of hospital pharmaceutical expenditure. This expenditure is likely to increase as a result on the one hand of the entry of new biotechnological drugs, more costly than traditional therapies, and, on the other hand, from the extension of indications of many drugs already on the market.